Drugs / c-kit+ cells
c-kit+ cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03406884 | Oct 2019 → Jul 2024 | hypoplastic left heart syndrome | Joshua M Hare | Completed | Mixed |
| Phase 21 trial | ||||||
| Phase 2 | NCT02501811 | Oct 2015 → Jun 2020 | cardiomyopathy | The University of Texas Health Science Center, Houston | Completed | Mixed |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | c-kit+ cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02501811 ↗ |
| Known as | Autologous c-kit-positive cells (c-kit+ cells) | “Autologous c-kit-positive cells (c-kit+ cells)” NCT03406884 ↗ |
| Known as | c-kit-positive cardiac progenitor cells | “mesenchymal stromal cells (MSCs) and c-kit-positive cardiac progenitor cells (CPCs)” PMID 42003602 ↗ Apr 2026 |
| Known as | CPCs | “mesenchymal stromal cells (MSCs) and c-kit-positive cardiac progenitor cells (CPCs)” PMID 42003602 ↗ Apr 2026 |
| Route | Other | “15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle” NCT02501811 ↗ |